<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127916">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436968</url>
  </required_header>
  <id_info>
    <org_study_id>PrTK03</org_study_id>
    <nct_id>NCT01436968</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer</brief_title>
  <acronym>PrTK03</acronym>
  <official_title>A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advantagene, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advantagene, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in
      combination with radiation therapy for patients with intermediate-high risk localized
      prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing
      tumor cells in an immune stimulatory environment induces the body's immune system to detect
      and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity
      and lower than expected recurrence rates in previous clinical trials. The hypothesis is that
      ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer.
      Participants will be randomized to the ProstAtak or control arm at a 2:1 ratio. Both arms
      receive standard external beam radiation therapy. Short-term androgen deprivation therapy
      may be given but is not required.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.</measure>
    <time_frame>Assessed at each visit every 6 months through year 5 until event occurs.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer specific survival and overall survival will be compared for the ProstAtak® arm versus the placebo control arm.</measure>
    <time_frame>Assessed at each visit every 6 months through year 5 after which long-term follow up of general health status will continue yearly.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA nadir will be compared for the ProstAtak® arm versus the placebo control arm.</measure>
    <time_frame>Assessed at each visit every 6 months through year 5.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Health Related Quality of Life outcomes will be collected using the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire. The change in QOL over time will be compared for the ProstAtak® arm versus the placebo control arm.</measure>
    <time_frame>Assessed at baseline and at 3, 6, 12, 18 and 24 months after completion of radiation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety profile will be characterized by collection of adverse event information and laboratory values during the treatment phase (until the completion of radiation). Data on late effects will be collected after radiation completion.</measure>
    <time_frame>Assessed at each visit and continuously throughout the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">711</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ProstAtak®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProstAtak® (AdV-tk) + valacyclovir + radiation therapy +/- ADT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + valacyclovir + radiation therapy +/- ADT</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProstAtak®(AdV-tk) + valacyclovir</intervention_name>
    <description>Patients will receive three courses of ProstAtak® each consisting of AdV-tk injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:
The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.
The second injection will be 0-3 days before initiation of radiation therapy.
The third injection will be 15-22 days after the 2nd injection.
The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.
Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.</description>
    <arm_group_label>ProstAtak®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo + valacyclovir</intervention_name>
    <description>Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:
The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.
The second injection will be 0-3 days before initiation of radiation therapy.
The third injection will be 15-22 days after the 2nd injection.
The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.
Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          -  Localized prostate cancer meeting the NCCN criteria of Intermediate Risk or patients
             having only one NCCN high-risk feature

               -  NCCN Intermediate Risk is defined as having at least one of the following: PSA
                  10-20 ng/ml, Gleason score =7, T2b-T2c

               -  High Risk with a single high risk feature is defined as having only one of the
                  following: PSA&gt;20 ng/ml, Gleason score 8-10, or T3a

               -  Excluded are those in the following risk groups: Low risk; High risk with more
                  than 1 high risk factor; Locally advanced/very high risk=T3b-T4; Metastatic: N1
                  or M1

          -  Planning to undergo standard prostate-only external beam radiation therapy

          -  ECOG Performance Status 0-2

        Exclusion Criteria include:

          -  Liver disease, including known cirrhosis or active hepatitis

          -  Patients on systemic corticosteroids (&gt;10mg prednisone per day) or other
             immunosuppressive drugs

          -  Known HIV+ patients

          -  Regional lymph node involvement or distant metastases

          -  Patients planning to receive whole pelvic irradiation

          -  Prior treatment for prostate cancer, except TURP or ADT. For ADT, it may only be
             given for a maximum of 6 months

          -  Patients who had or plan to have orchiectomy as the form of hormonal ablation

          -  Known sensitivity or allergic reactions to acyclovir or valacyclovir
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Oncology Services Foundation</name>
      <address>
        <city>Phoenix, Mesa, Scottsdale, Sedona</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Genitourinary Surgical Consultants</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Basefsky</last_name>
      <phone>303-320-0120</phone>
      <email>jessica.basefsky@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Snyder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Urology</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dani Puga</last_name>
      <phone>303-985-2550</phone>
      <email>dani@foothillsurologypc.com</email>
    </contact>
    <investigator>
      <last_name>David Cahn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Urology</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damian Sorce, MD</last_name>
      <phone>720-457-8362</phone>
    </contact>
    <investigator>
      <last_name>Damian Sorce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Penn, RN</last_name>
      <phone>410-502-9242</phone>
      <email>kpurcel2@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christina Rodriguez</last_name>
      <phone>410-614-3158</phone>
      <email>crodri38@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Theodore DeWeese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith A. Travis, RN, CCRC</last_name>
      <phone>301-319-2927</phone>
      <email>judith.a.travis.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Inger L. Rosner, MD, MC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret R Humphries, RN, CCRC</last_name>
      <phone>508-856-5711</phone>
      <email>Margaret.Humphries@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Mitchell H. Sokoloff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Oncology Hematology Consultants (NMOHC)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Yost</last_name>
      <phone>505-243-4039</phone>
      <email>research@nmohc.com</email>
    </contact>
    <investigator>
      <last_name>Gregg Franklin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Fischer</last_name>
      <phone>505-925-7487</phone>
      <email>mjfischer@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Lopez</last_name>
      <phone>505-925-0375</phone>
      <email>slopez@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas M. Schroeder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-932-6008</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York</name>
      <address>
        <city>Hartsdale</city>
        <state>New York</state>
        <zip>10530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-932-6008</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York</name>
      <address>
        <city>Hauppauge</city>
        <state>New York</state>
        <zip>11749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-932-6008</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J. Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
    <investigator>
      <last_name>Michael J. Zelefsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York (Integrated Medical Professionals)</name>
      <address>
        <city>North Hills</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-394-9600</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-932-6008</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York</name>
      <address>
        <city>West Nyack</city>
        <state>New York</state>
        <zip>10994</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-932-6008</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Leahy, RN, BSN</last_name>
      <phone>215-728-2994</phone>
      <email>Joan.Leahy@fccc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Lech, RN</last_name>
      <phone>215-728-2994</phone>
      <email>Melissa.Lech@fccc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Reeves, RN-BSN, CCRC</last_name>
      <phone>214-580-1391</phone>
      <email>reeves@urologyclinics.com</email>
    </contact>
    <investigator>
      <last_name>James S. Cochran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Irving Fishman's Office</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Fishman</last_name>
      <phone>713-790-1800</phone>
      <email>miriamfishman@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Irving Fishman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Willowbrook Radiation Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maegan Elliott</last_name>
      <phone>281-351-5174</phone>
      <email>Maegan.elliott@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Chase Authement</last_name>
      <phone>281-351-5174</phone>
      <email>Chase.Authement@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Abhilasha Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Ned Stein's Office</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ned Stein, MD</last_name>
      <phone>713-776-8888</phone>
    </contact>
    <investigator>
      <last_name>Ned Stein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Millennium Radiation Center - The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maegan Elliott</last_name>
      <phone>281-351-5174</phone>
      <email>Maegan.elliott@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Chase Authement</last_name>
      <phone>281-351-5174</phone>
      <email>Chase.Authement@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Berilgen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Urology Specialists</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maegan Elliott</last_name>
      <phone>281-351-5174</phone>
      <email>Maegan.elliott@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Chase Authement</last_name>
      <phone>281-351-5174</phone>
      <email>Chase.authement@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Steven W. Sukin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>September 19, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy, cytotoxicity, tumor vaccine, prostate cancer, radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
